Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    Bliss Family Fund to Advance Cellular Therapies for WM

    Bliss Family Fund to Advance Cellular Therapies for WM supports investigators conducting trials of novel cellular immunotherapies and immune-redirection strategies to improve WM remissions and disease control.

    OverviewSimilar Grants
    OverviewSimilar Grants

    This grant was recently updated

    The application deadline was extended from November 9, 2026, to January 26, 2027.

    Funder: International Waldenstrom's Macroglobulinemia Foundation

    Due Dates: November 9, 2026 (Inaugural RFP closing) | January 26, 2027 (RFP due)

    Funding Amounts: Up to $1,000,000 USD over 2–4 years

    Summary: Supports investigator-initiated clinical trials of innovative cellular immunotherapies and immune-redirection strategies for Waldenstrom macroglobulinemia.

    Key Information: PIs must hold a doctoral degree and a full-time independent research or academic position at the sponsoring institution.


    Description

    The Bliss Family and International Waldenstrom's Macroglobulinemia Foundation (IWMF) support investigator-initiated trials of distinctly novel cellular immunotherapies and immune-redirection strategies for Waldenstrom macroglobulinemia (WM). Supported approaches include autologous or allogeneic cell therapies, CAR-T and CAR-NK platforms, bispecific and trispecific immune engagers, next-generation engineered cellular approaches, and rational immune-based combinations.

    The program seeks clinically meaningful benefit within 3–5 years, including deeper, more durable remissions, complete responses, MRD-negativity, and improved disease control. Studies should establish clinical proof-of-concept supporting larger trials and future regulatory approval or guideline inclusion. Strategies addressing WM-associated immune dysfunction, T-cell exhaustion, and the immune microenvironment are also of interest, including sequencing approaches and earlier intervention in high-risk populations. Correlative studies are welcome where they strengthen interpretation and inform therapeutic development.


    Atom

    See the full grant listing

    Sign in to view full eligibility details, sources, similar grants, and AI-powered analysis.